ENCHROMA
15.7.2024 18:09:34 CEST | Business Wire | Press release
Opera di Religione della Diocesi di Ravenna, EnChroma, manufacturers of lenses for color blind users, Francesca Carlone, sustainable designer and founder of the project, Fondazione Paolina Brugnatelli and ITRIA announce today an initiative to enhance the experience of color blind visitors. Starting July 19, 2024, visitors with this vision condition will be able to borrow special glasses during their visit to live for the first time the experience of seeing light and bright color mosaics. The project, called ColoRaMi - color mosaics, will be introduced on July 19 at Basilica di Sant’Apollinare Nuovo as part of the Ravenna Mosaici FOR ALL program.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240714597763/en/
Basilica di San Vitale: Agnus Dei. Normal colour vision and colour blind view (Graphic: Business Wire)
In Italy, approximately 2.5 million people are color blind, a vision condition affecting a higher number of men (8%) vs. women (0.5%) and approximately 350 million people worldwide. Whereas people with normal color vision can see over one million shades of color, people with color vision deficit only see 10% of tones and shades. As a result, colors can appear dull or even indistinguishable. EnChroma lenses allow people with deuteranomaly and protanomaly to perceive a much wider range of colors.
Artistic and cultural heritage is enhanced also by improving its accessibility, safety, and inclusiveness. Thanks to ColoRaMi, Ravenna's Mosaics will be the world's first mosaics to be made accessible to color blind people. Starting Friday, July 19, EnChroma glasses will be distributed free of charge at the following locations: Basilica of Sant’Apollinare Nuovo, Mausoleum of Galla Placidia, Basilica of San Vitale, Neonian Baptistry, Archiepiscopal Museum, and Sant’Andrea Chapel, thus enabling visitors to see for the first time the mosaics in all their chromatic complexity.
The opening event on July 19, at 3:00 p.m. will host a “live reveal” event, in which a number of color blind participants will share the daily challenges of color blindness and the difference made by EnChroma lenses in their viewing experience of the multicolor nuances of the mosaics.
EVENT INFO:
When: Friday, July 19 at 3:00 p.m.
Where: Basilica of Sant’Apollinare Nuovo
What's a Live Reveal:
A "Live Reveal" is an opportunity for volunteers to test EnChroma glasses for the first time and share their experience. At the end of the day, the volunteers may keep their custom-made glasses.
About EnChroma glasses:
EnChroma glasses are the product of two NIH research grants and of clinical studies conducted at UC Berkeley and UC Davis, USA. In 2016, EnChroma glasses were awarded the Tibbetts Award by the U.S. Small Business Administration for their innovative technology-driven impact on individual experience. EnChroma glasses use special optical filters that help people with color vision deficiency (protanomaly and deuteranomaly) experience a wider range of colors, perceiving them as more accurate, brighter, and sharper. Please note: EnChroma glasses do not treat color blindness and work for 9 out of 10 color blind wearers.
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240714597763/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
